25th Annual Meeting of the Society of Urologic Oncology (SUO)

  04 Dec 2024 - 06 Dec 2024

   Dallas, TX, United States

conference-img

25th Annual Meeting of the Society of Urologic Oncology (SUO)

04 Dec 2024

 - 

06 Dec 2024

Dallas, TX, United States



The 25th Annual Scientific Meeting in Urologic Oncology will be held December 4 – 6, 2024, at the Sheraton Dallas Hotel. The Society of Urologic Oncology will sponsor this highly interactive meeting where attendees participate in discussions led by internationally renowned urologic oncologists.

Medical oncologists, and scientists. State-of-the-art translational topics on prostate, kidney, and bladder cancer, as well as strategies in urologic oncology, will be discussed. There will be a half-day session on Wednesday morning on Clinical Research to ensure that fellows have the tools required to quickly engage in clinical trials upon graduation and to facilitate engagement in the SUO-CTC.

International Conference on Medical and Health Sciences

On: 25 May 2026

-

26 May 2026


International Conference on Sexual and Reproductive Health

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Medical and Health Sciences

On: 25 May 2026

-

26 May 2026


International Conference on Sexual and Reproductive Health

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026



Whats more on Hidoc Dr.


Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer

Recommended News For You

Conferences That Might Interest You

Recommended Articles For You

Boost Your Knowledge With These Quizzes





© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot